cancer

A UCLA-led study could lead to a new strategy for treating the aggressive form of brain cancer.

The inaugural chair holder is Dr. Beth Karlan, a UCLA professor of obstetrics and gynecology.

Jonsson Comprehensive Cancer Center scientists adapted advanced gene-editing technology to make their observations.

A therapeutic sponge the size of a pencil eraser boosted tumor-fighting responses in mice and kept cancer from returning.

The discovery could be a step toward improved treatment for glioblastoma multiforme.

When two drugs were delivered in one nanoparticle rather than separately, the treatment worked better in mice.

Research led by UCLA links prenatal exposure to specific chemicals to higher rates of eye cancer.

A new study in mice suggests that adding iNKT cells to a stem cell transplant could reduce complication severity.

The study could eventually lead to more treatment options for leukemia, sickle cell disease and other conditions.

The oral medication, ERAS-801, targets a rogue gene found in about 60% of people with the aggressive form of brain cancer.

The findings could improve doctors’ ability to offer truly personalized cancer therapy.

A UCLA study suggests that new small-molecule drugs that inhibit a protein called ATR could be used in combination with interferon “amplification.”

The veteran firefighter, who expects to earn his Ph.D. in chemistry in winter quarter, is using his knowledge to improve the health and safety of his colleagues.

Using stem cell engineering and organoid technology, UCLA researchers were able to produce large quantities of powerful cancer-fighting iNKT cells.

A team led by UCLA scientists found that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone.

UCLA researchers discover that MAOIs could activate immune system to shrink various types of tumors.

The research, conducted on mice, targets a newly discovered molecular “checkpoint” that enables cancer stem cells to evade the immune system.

Overweight children participating in the intervention were 70% less likely to have detectable cancer cells after one month of treatment.

Only 1 in 10 people diagnosed with this aggressive disease live beyond five years, and most current therapies have been unsuccessful in treating it.

The study, conducted in mice, opens a path for exploring treatments that combine epigenetic approaches with therapies that use the body’s natural immune response.

Research brief: Improving imaging processes will lead to more successful treatments and help reduce morbidity in men with the disease.

Research brief: The new finding highlights the need for alternative therapies for patients who are resistant to chemotherapy and radiation.

The new method should become the standard of care, say researchers from both universities who validated its effectiveness.

UCLA research paves the way for new diagnostic and therapeutic approaches.

Brown, a UCLA alumna and member of UCLA’s Jonsson Comprehensive Cancer Center, died Oct. 4 at her home in Los Angeles.